KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2025)

Ginkgo Bioworks Holdings' Cash from Financing Activities history spans 6 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 4110.84% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $17.8 million, up 1122.14%, while the annual FY2025 figure was $17.8 million, 1122.14% up from the prior year.
  • Cash from Financing Activities reached $8.1 million in Q4 2025 per DNA's latest filing, down from $9.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $1.5 billion in Q3 2021 to a low of -$11.0 million in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $82.1 million, with a median of -$412000.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: tumbled 5837.1% in 2021, then soared 4110.84% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$11.0 million in 2021, then soared by 985.29% to $97.8 million in 2022, then plummeted by 100.65% to -$632000.0 in 2023, then soared by 67.88% to -$203000.0 in 2024, then skyrocketed by 4110.84% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Cash from Financing Activities are $8.1 million (Q4 2025), $9.9 million (Q3 2025), and -$98000.0 (Q2 2025).